logo

For the Inventor, By the Inventor

Barcelona, Spain

Alberto Dordal Zueras

This inventor holds 18 USPTO granted patents and 3 published patent applications and 6 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Laboratorios Del Dr. Esteve S.a., Esteve Laboratorios Dr. Esteve S.a., Laboratories Del Dr. Esteve S.a.. Active years: 2006-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alberto Dordal Zueras. Retrieved from https://idiyas.com/inventor/alberto-dordal-zueras

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 18 

% Patents Active = 11.1


Average Co-Inventor Count = 4.9

ph-index = 4

Forward Citations = 54(Granted Patents)


Company Filing History:

goldMedal15 out of 150 
 
Laboratorios Del Dr. Esteve S.a.
 patents
silverMedal2 out of 2 
 
Esteve Laboratorios Dr. Esteve S.a.
 patents
bronzeMedal1 out of 23 
 
Laboratories Del Dr. Esteve S.a.
 patents

Years Active: 2006-2013

Loading Chart...
Loading Chart...
Areas of Expertise:
Sigma Receptor Inhibitors
5-HT7 Antagonists
Triazole Derivatives
Indol Sulfonamide Derivatives
Neuropeptide Y5 Ligands
Benzoxazinone Compounds
Pharmaceutical Compositions
Modulators
18 patents (USPTO):Explore Patents
1. 8349878 - 1,2,4-triazole derivatives as sigma receptor inhibitors (2013-01-08),
2. 8193223 - 1,2,3-triazole derivatives as sigma receptor inhibitors (2012-06-05),
3. 8188115 - [object Object] (2012-05-29),
4. 8148397 - 5-HT7 receptor antagonists (2012-04-03),
5. 8097643 - Indol-4 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators (2012-01-17),
6. 8039497 - 1,2,4-triazole derivatives as sigma receptor inhibitors (2011-10-18),
7. 7928121 - 5-HT7 receptor antagonists (2011-04-19),
8. 7888510 - 2-'4(phenylamino)-piperidin-1-yl!-n-phenyl-acetamine derivatives and related compounds as neuropeptide Y5 (NPY5) ligands for the treatment of obesity (2011-02-15),
9. 7662862 - [object Object] (2010-02-16),
10. 7655690 - [object Object] (2010-02-02),
11. 7553965 - [object Object] (2009-06-30),
12. 7514429 - Benzoxazinone-derived compounds, their preparation and use as medicaments (2009-04-07),
13. 7462640 - Indol-6yl sulfonamide derivatives, their preparation and their use as 5-HT-6 as modulators (2008-12-09),
14. 7414070 - Indol-7-YL sulfonamide derivatives, their preparation and their use in pharmaceutical compositions (2008-08-19),
15. 7345057 - 5-HT7 receptor antagonists (2008-03-18),

Title: The Innovative Contributions of Alberto Dordal Zueras

Introduction

Alberto Dordal Zueras is a prominent inventor based in Barcelona, Spain. He has made significant contributions to the field of pharmacology, particularly through his innovative work on sigma receptor inhibitors. With a total of 18 patents to his name, Zueras has established himself as a key figure in the development of new therapeutic compounds.

Latest Patents

Among his latest patents are two notable inventions: the first involves 1,2,4-triazole derivatives as sigma receptor inhibitors. This invention focuses on the use of compounds that exhibit pharmacological activity towards the sigma receptor, specifically 1,2,4-triazole derivatives of a defined formula. The second patent pertains to 1,2,3-triazole derivatives as sigma receptor inhibitors, which also target the sigma receptor and are aimed at therapeutic applications, particularly for treating psychosis or pain.

Career Highlights

Zueras has worked with esteemed companies such as Laboratorios del Dr. Esteve S.A. and Esteve Laboratorios Dr. Esteve S.A. His work in these organizations has allowed him to further his research and development efforts in the pharmaceutical industry.

Collaborations

Throughout his career, Zueras has collaborated with notable colleagues, including Antoni Torrens Jover and Luz Romero Alonso. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Alberto Dordal Zueras is a distinguished inventor whose work on sigma receptor inhibitors has the potential to impact therapeutic practices significantly. His extensive patent portfolio and collaborations highlight his commitment to innovation in pharmacology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…